Reduction of cyclophosphamide dose for patients with subset 2 low‐risk rhabdomyosarcoma is associated with an increased risk of recurrence: A report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group
暂无分享,去创建一个
James R. Anderson | J. Meza | A. Pappo | D. Hawkins | J. Breneman | T. Cripe | D. Parham | A. Hayes-Jordan | D. Walterhouse | William H Meyer | David M. Parham | Alberto S. Pappo | John C. Breneman | William H. Meyer
[1] S. Donaldson,et al. Delayed primary excision with subsequent modification of radiotherapy dose for intermediate‐risk rhabdomyosarcoma: A report from the Children's Oncology Group Soft Tissue Sarcoma Committee , 2015, International journal of cancer.
[2] C. Pui,et al. Cumulative alkylating agent exposure and semen parameters in adult survivors of childhood cancer: a report from the St Jude Lifetime Cohort Study. , 2014, The Lancet. Oncology.
[3] James R. Anderson,et al. Shorter-duration therapy using vincristine, dactinomycin, and lower-dose cyclophosphamide with or without radiotherapy for patients with newly diagnosed low-risk rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] James R. Anderson,et al. Vincristine, dactinomycin, cyclophosphamide (VAC) versus VAC/V plus irinotecan (VI) for intermediate-risk rhabdomyosarcoma (IRRMS): A report from the Children’s Oncology Group Soft Tissue Sarcoma Committee. , 2014 .
[5] J. Meza,et al. Local control and outcome in children with localized vaginal rhabdomyosarcoma: A report from the Soft Tissue Sarcoma committee of the Children's Oncology Group , 2011, Pediatric blood & cancer.
[6] James R. Anderson,et al. Results of the Intergroup Rhabdomyosarcoma Study Group D9602 protocol, using vincristine and dactinomycin with or without cyclophosphamide and radiation therapy, for newly diagnosed patients with low-risk embryonal rhabdomyosarcoma: a report from the Soft Tissue Sarcoma Committee of the Children's O , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] James R. Anderson,et al. Analysis of prognostic factors in patients with nonmetastatic rhabdomyosarcoma treated on intergroup rhabdomyosarcoma studies III and IV: the Children's Oncology Group. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[8] James R. Anderson,et al. Rhabdomyosarcoma: many similarities, a few philosophical differences. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[9] H. B. Marsden,et al. Treatment of nonmetastatic rhabdomyosarcoma in childhood and adolescence: third study of the International Society of Paediatric Oncology--SIOP Malignant Mesenchymal Tumor 89. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] James R. Anderson,et al. Intergroup rhabdomyosarcoma study-IV: results for patients with nonmetastatic disease. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[11] L. Diller,et al. High risk of infertility and long term gonadal damage in males treated with high dose cyclophosphamide for sarcoma during childhood , 2001, Cancer.
[12] A. Pappo,et al. Survival after relapse in children and adolescents with rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] E. Gehan,et al. The Third Intergroup Rhabdomyosarcoma Study. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[15] F. Askin,et al. Therapy-related myelodysplasia and acute myeloid leukemia after Ewing sarcoma and primitive neuroectodermal tumor of bone: A report from the Children's Oncology Group. , 2007, Blood.
[16] M. Stevens,et al. Treatment of orbital rhabdomyosarcoma: survival and late effects of treatment--results of an international workshop. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[17] R. Wittes,et al. Methodologic guidelines for reports of clinical trials. , 1985, Cancer treatment reports.